Advancing Genomic Technologies to Combat Infectious Disease: Mapping Dynamics within Single Cells, Individual Hosts, and Global Populations

推进基因组技术对抗传染病：绘制单细胞、个体宿主和全球人群的动态图

• 批准号: 10641432
• 负责人: Bruce W. BIRREN
• 金额: $ 138.47万
• 依托单位: BROAD INSTITUTE, INC.
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-09-01 至 2023-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10641432
• 关键词: Cells; Clinical; Communicable Diseases; Drug resistance; Enrollment; Genomics; Incidence; Individual; Outcome; Patients; Population; Reporting; Research Personnel; Risk Factors; Ritonavir; Symptoms; Syndrome; Technology; Viral; Viral Genome; Viral load measurement; cohort; combat; genome sequencing; nirmatrelvir; prospective; virology

Project Summary/Abstract Clinical rebound following treatment with nirmatrelvir-ritonar has been reported. The incidence, virology, and clinical consequence of this syndrome are not clear. The investigators will conduct a study of nirmatrelvir-ritonavir rebound with the following objectives: Objective 1: Determine the incidence and risk factors for symptomatic and asymptomatic virologic rebound after nirmatrelvir-ritonavir therapy Objective 2: Determine the duration and magnitude of virologic rebound and contagiousness of symptomatic and asymptomatic rebound after nirmatrelvir-ritonavir therapy Objective 3: Estimate the incidence of treatment-emergent drug resistance after rebound Objective 4: Describe clinical outcomes with and without virologic rebound following nirmatrelvir-ritonavir therapy in a real-world setting By carrying out these objectives, the investigators will define the incidence of rebound after nirmatrelvir-ritonavir and characterize the associated syndrome using quantitative measurement of viral load, viral culture, and whole virus genome sequencing.

项目概要/摘要 据报道，用 nirmatrelvir-ritonar 治疗后出现临床反弹。发病率, 该综合征的病毒学和临床后果尚不清楚。调查人员将进行 一项尼尔马瑞韦-利托那韦反弹研究，其目标如下： 目标 1：确定有症状和无症状的发病率和危险因素 尼马曲韦-利托那韦治疗后病毒学反弹 目标 2：确定病毒学反弹和传染性的持续时间和程度 尼马曲韦-利托那韦治疗后有症状和无症状反弹 目标 3：估计反弹后治疗中出现的耐药性的发生率 目标 4：描述以下情况下有或没有病毒学反弹的临床结果 现实环境中的尼尔马韦-利托那韦治疗 通过实现这些目标，研究人员将确定术后反弹的发生率 尼尔马瑞韦-利托那韦并使用定量测量来表征相关综合征 病毒载量、病毒培养和全病毒基因组测序。

项目成果

Integration of whole genome sequencing and transcriptomics reveals a complex picture of the reestablishment of insecticide resistance in the major malaria vector Anopheles coluzzii.

• DOI: 10.1371/journal.pgen.1009970
• 发表时间: 2021-12
• 期刊: PLoS genetics
• 影响因子: 4.5
• 作者: Ingham VA;Tennessen JA;Lucas ER;Elg S;Yates HC;Carson J;Guelbeogo WM;Sagnon N;Hughes GL;Heinz E;Neafsey DE;Ranson H
• 通讯作者: Ranson H

Field-deployable viral diagnostics using CRISPR-Cas13.

• DOI: 10.1126/science.aas8836
• 发表时间: 2018-04-27
• 期刊: Science (New York, N.Y.)
• 作者: Myhrvold C;Freije CA;Gootenberg JS;Abudayyeh OO;Metsky HC;Durbin AF;Kellner MJ;Tan AL;Paul LM;Parham LA;Garcia KF;Barnes KG;Chak B;Mondini A;Nogueira ML;Isern S;Michael SF;Lorenzana I;Yozwiak NL;MacInnis BL;Bosch I;Gehrke L;Zhang F;Sabeti PC
• 通讯作者: Sabeti PC

Evidence of extensive DNA transfer between bacteroidales species within the human gut.

• DOI: 10.1128/mbio.01305-14
• 发表时间: 2014-06-17
• 期刊: mBio
• 影响因子: 6.4
• 作者: Coyne MJ;Zitomersky NL;McGuire AM;Earl AM;Comstock LE
• 通讯作者: Comstock LE

Genomic characterization of recurrent mold infections in thoracic transplant recipients.

胸腔移植受者复发性霉菌感染的基因组特征。

• DOI: 10.1111/tid.12935
• 发表时间: 2018
• 期刊: Transplant infectious disease : an official journal of the Transplantation Society
• 作者: Messina,JuliaA;Wolfe,CameronR;Hemmersbach-Miller,Marion;Milano,Carmelo;Todd,JamieL;Reynolds,John;Alexander,BarbaraD;Schell,WileyA;Cuomo,ChristinaA;Perfect,JohnR
• 通讯作者: Perfect,JohnR

The Anopheles coluzzii microbiome and its interaction with the intracellular parasite Wolbachia.

库氏按蚊微生物组及其与细胞内寄生虫沃尔巴克氏体的相互作用。

• DOI: 10.1038/s41598-020-70745-0
• 发表时间: 2020
• 期刊: Scientific reports
• 影响因子: 4.6
• 作者: Straub,TimothyJ;Shaw,WRobert;Marcenac,Perrine;Sawadogo,SimonP;Dabiré,RochK;Diabaté,Abdoulaye;Catteruccia,Flaminia;Neafsey,DanielE
• 通讯作者: Neafsey,DanielE